Chlorprothixene HCl | CAS#113-59-7 | Serotonin Antagonist

MedKoo Cat#: 317519 | Name: Chlorprothixene HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Chlorprothixene HCl is a typical antipsychotic drug of the thioxanthene class and was the first of the series to be synthesized. It is a potent, non-selective dopamine, 5-HT and H1 receptor antagonist. Chlorprothixene does also act as FIASMA- functional inhibitor of acid sphingomyelinase. Chlorprothixene HCl is available via prescription only (within the USA).

Chemical Structure

Chlorprothixene HCl

CAS#6469-93-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 317519

Name: Chlorprothixene HCl

CAS#: 6469-93-8 (HCl)

Chemical Formula: C18H19Cl2NS

Exact Mass: 0.0000

Molecular Weight: 352.32

Elemental Analysis: C, 61.36; H, 5.44; Cl, 20.12; N, 3.98; S, 9.10

Price and Availability

Size	Price	Availability
1g	USD 250.00	2 Weeks
5g	USD 550.00	2 Weeks
10g	USD 850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

6469-93-8 (HCl) 113-59-7 (free base)

Synonym

Chlorprothixene; Truxal; Taractan; Minithixen; NSC 169899; NSC 56379; NSC 78193; Truxal hydrochloride; cis-Chlorprothixene

IUPAC/Chemical Name

(Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine hydrochloride

InChi Key

YWKRLOSRDGPEJR-KIUKIJHYSA-N

InChi Code

InChI=1S/C18H18ClNS.ClH/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18;/h3-4,6-10,12H,5,11H2,1-2H3;1H/b14-7-;

SMILES Code

CN(C)CC/C=C1C2=C(SC3=C\1C=CC=C3)C=CC(Cl)=C2.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 352.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Skov L, Johansen SS, Linnet K. Postmortem femoral blood reference concentrations of aripiprazole, chlorprothixene, and quetiapine. J Anal Toxicol. 2015 Jan-Feb;39(1):41-4. doi: 10.1093/jat/bku121. Epub 2014 Oct 22. PubMed PMID: 25342720. 2: Käferstein H, Sticht G, Madea B. Chlorprothixene in bodies after exhumation. Forensic Sci Int. 2013 Jun 10;229(1-3):e30-4. Epub 2013 Apr 28. PubMed PMID: 23821789. 3: Chen YW, Chu CC, Chen YC, Leung YM, Wang JJ. Intrathecal chlorprothixene, cis(z)-flupenthixol, chlorpromazine and fluphenazine for prolonged spinal blockades of sensory and motor functions in rats. Eur J Pharmacol. 2012 Oct 15;693(1-3):31-6. doi: 10.1016/j.ejphar.2012.07.039. Epub 2012 Aug 21. PubMed PMID: 22926199. 4: Santiago LE, García C, Lhiaubet-Vallet V, Miranda MA, Oyola R. Solvent dependence of the photophysical properties of 2-chlorothioxanthone, the principal photoproduct of chlorprothixene. Photochem Photobiol. 2011 May-Jun;87(3):611-7. doi: 10.1111/j.1751-1097.2011.00906.x. Epub 2011 Mar 8. PubMed PMID: 21294748; PubMed Central PMCID: PMC3082582. 5: Piñero LE, García C, Lhiaubet-Vallet V, Oyola R, Miranda MA. Photophysics and photochemistry of z-chlorprothixene in acetonitrile. Photochem Photobiol. 2009 Jul-Aug;85(4):895-900. PubMed PMID: 19708200. 6: Karpińska J, Szostak J. Determination of chlorprothixene and amitryptyline hydrochlorides by UV-derivative spectrophotometry and UV-solid-phase spectrophotometry. Spectrochim Acta A Mol Biomol Spectrosc. 2005 Mar;61(5):975-81. PubMed PMID: 15683805. 7: Meyer S, Gottschling S, Georg T, Lothschütz D, Graf N, Sitzmann FC. Gamma-hydroxybutyrate versus chlorprothixene/phenobarbital sedation in children undergoing MRI studies. Klin Padiatr. 2003 Mar-Apr;215(2):69-73. PubMed PMID: 12677545. 8: Bagli M, Süverkrüp R, Quadflieg R, Höflich G, Kasper S, Möller HJ, Langer M, Barlage U, Rao ML. Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. J Pharmacol Exp Ther. 1999 Nov;291(2):547-54. PubMed PMID: 10525070. 9: Lepp U, Schlaak M, Schulz KH. Contact dermatitis to chlorprothixene. Allergy. 1998 Jul;53(7):718-9. PubMed PMID: 9700045. 10: Luisto M. Polyneuropathy caused by chlorprothixene. Acta Psychiatr Scand. 1992 Mar;85(3):246-8. PubMed PMID: 1314010. 11: Sylte I, Dahl SG. Three-dimensional structure and molecular dynamics of cis(Z)- and trans(E)-chlorprothixene. J Pharm Sci. 1991 Aug;80(8):735-40. PubMed PMID: 1791531. 12: Rosler KH, Wright J, Fox KM, Waters RM, Callery PS. A nuclear magnetic resonance (NMR) method for the determination of the cis/trans isomeric content of chlorprothixene. Pharm Res. 1989 Aug;6(8):706-8. PubMed PMID: 2813263. 13: Laux G, Koenig W, Pfaff G. Antidepressant combination therapy of endogenous depressions with benzodiazepines or neuroleptics--a study comparing adjuvant treatment with oxazolam versus chlorprothixene. Pharmacopsychiatry. 1988 Mar;21(2):87-92. PubMed PMID: 2899329. 14: Scheithauer W, Ulrich W, Kovarik J, Stummvoll HK. Acute oliguria associated with chlorprothixene overdosage. Nephron. 1988;48(1):71-3. PubMed PMID: 3340257. 15: Gunich LA, Vishnevskiĭ BI, Volkon VM. [Effectiveness of chlorprothixene in the combined treatment of pulmonary tuberculosis patients]. Probl Tuberk. 1986;(8):35-9. Russian. PubMed PMID: 3774792. 16: Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group. Psychopharmacology (Berl). 1986;90(4):423-9. PubMed PMID: 2880362. 17: Breyer-Pfaff U, Wiest E, Prox A, Wachsmuth H, Protiva M, Sindelár K, Friebolin H, Krauss D, Kunzelmann P. Phenolic metabolites of chlorprothixene in man and dog. Drug Metab Dispos. 1985 Jul-Aug;13(4):479-89. PubMed PMID: 2863114. 18: Horodnicki JM, Czekalski S, Jarema M, Kubasiewicz A, Pobocha J, Wdowiak J. [Comparison of the effects of chlorprothixene and haloperidol on hypothalamic function in patients with paranoid schizophrenia]. Psychiatr Pol. 1985 May-Jun;19(3):181-7. Polish. PubMed PMID: 3913968. 19: Brooks MA, DiDonato G, Blumenthal HP. Determination of chlorprothixene and its sulfoxide metabolite in plasma by high-performance liquid chromatography with ultraviolet and amperometric detection. J Chromatogr. 1985 Feb 8;337(2):351-62. PubMed PMID: 3988865. 20: Poling A, Picker M, Thomas J. Effects of chlorprothixene, haloperidol, and trifluoperazine on the delayed-matching-to-sample performance of pigeons. Pharmacol Biochem Behav. 1984 Nov;21(5):721-6. PubMed PMID: 6151195.